SalesForce4Hire's Kevin Schimelfenig Featured In OneMedSentinel
Written by
Herina Ayot on Jun 20, 2011
For many emerging healthcare and life science companies, one of their largest financial investments and most important strategic decisions is their approach to sales and distribution. Determining the most optimal exit strategy is central to how emerging companies approach its sales and distribution model.
In order to maximize valuation and minimize dilution at exit as well as minimize risk for the buyer, it is extremely important to choose the most optimal sales strategy to attract an acquiring company. If for example the acquiring company has its own national sales force, then building a full-scale sales and distribution model could be detrimental and may in fact negatively affect the sale. Instead finding ways to gain market traction on a small scale, with a proven scalable model may be more efficient and less costly.
A special panel at OneMedForum NY 2011 will discuss the critical considerations involved in building a sales model to facilitate a successful exit, and will offer a variety of perspectives for the healthcare or life science buyer, seller and investor.
Panelists include Kevin Schimelfenig, Managing Partner, McGeever, LLC and SalesForce4Hire, LLC; Michael Cain, Founder and Managing Partner, Guardant Partners LLC; and Kevin Nickels, CEO of Rubigo Therapeutics.
To read the full article by OneMedPlace visit http://www.onemedplace.com/blog/archives/8681.
